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extracellular matrix gene expression
LESLIE A. BRUGGEMAN, JILL A. PELLICORO, ELIZABETH A. HORIGAN,
and PAUL E. KLOTMAN
Molecular Medicine Section, Laboratory of Developmental Biology, National institute of Dental Research, National Institutes of Health,
Bethesda, Maryland, USA
Thromboxane and prostacyclin differentially regulate murine extracel-
lular matrix gene expression. Alterations in the arachidonic acid metab-
olites thromboxane and prostacyclin are known to contribute to hemo-
dynamic changes observed in certain models of acute and chronic renal
failure. We have previously shown that thromboxane may have an
important role in mediating glomerulosclerosis by stimulating the ex-
pression of certain extracellular matrix proteins. In the present study,
we compared the effects of thromboxane and prostacyclin on the
expression of genes encoding basement membrane proteins using a
murine teratocarcinoma cell line, that when differentiated to an endo-
dermal phenotype synthesizes abundant extracellular matrix. Incuba-
tion of these cells with stable analogs of thromboxane and prostacyclin
for four hours resulted in changes in basement membrane gene expres-
sion. Thromboxane increased steady-state mRNA levels for all three
laminin chains, type IV collagen, and fibronectin, but decreased the
level of mRNA for heparan sulfate proteoglycan. In contrast, incuba-
tion with carbo-prostacyclin, a stable analog of prostacyclin, decreased
the steady-state mRNA level for the laminin A and B 1 chains, type IV
collagen and fibronectin, and increased the mRNA level for heparan
sulfate proteoglycan and laminin B2. Carbo-prostacyclin did not affect
cellular proliferation or thymidine incorporation. These results indicate
that eicosanoids directly modulate matrix gene expression indepen-
dently of hemodynamic influence, and independently of effects medi-
ated by platelets, or mitogenesis. Furthermore, these findings suggest
that the alterations in renal eicosanoid metabolism may directly partic-
ipate in the pathogenesis of glomeruloscierosis and thus provide a
rationale for therapy directed toward the specific inhibition of throm-
boxane in the treatment of progressive glomerular sclerosis.
The arachidonic acid metabolites, thromboxane A2 (TXA2)
and prostacyclin (PGI2), are autacoids that modulate renal
function 11—3, and reviewed in 4] and affect platelet aggregation
[5—9]. Altered local synthesis of TXA2 and PG!2 have been
shown to be important contributors to the hemodynamic
changes observed with certain models of acute renal failure [4].
In addition, chronically diseased kidneys produce increased
quantities of TXA2 [reviewed in 4 and 10] and often reduced
quantities of PGI2 [11—13]. Although circulating concentrations
of TXA2 are normally quite low [141, platelet deposition in
glomeruli [15—17], infiltrating activated macrophages [18—21] or
cells within the kidney parenchyma can generate local concen-
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trations of thromboxane in the micromolar range [22—26]. Thus,
under pathological conditions, the production of TXA2 can be
quite high and PGI2 production may be unchanged or reduced.
Accumulating evidence now suggests that arachidonic acid
metabolites may directly participate in the stimulation of gene
expression independent of their well-known effects in modulat-
ing hemodynamics and platelet aggregation. Horiguchi et al [27]
have shown that leukotriene B4 and prostaglandin E2 (PGE2)
play key roles in the ability of phorbol esters to stimulate tumor
necrosis factor alpha (TNFa). This study concluded that a
balance between the activity of 5-lipoxygenase and cyclooxy-
genase regulates TNFa gene expression. Similarly, Varga Ct al
[28] have shown that PGE2 increases the steady state mRNA
for the genes encoding fibronectin and types I and III collagen
in dermal fibroblasts in culture. These increases did not result
from changes in mRNA stability, suggesting that PGE2 directly
affects initiation of transcription. Recently, we have shown that
stable analogs of TXA2 increase the expression of the genes
encoding fibronectin, type IVal collagen, and laminin B2 as
well as protein production by differentiated F9 teratocarcinoma
cells and renal mesangial cells [291.
In the present study, we have compared the effects of
thromboxane on matrix gene expression to those of prostacy-
din using mouse teratocarcinoma cells in culture. We measured
the effects of U46619, a stable analog of TXA2, and carbo-
prostacyclin, a PG!2 analog, on the steady-state mRNA levels
of laminin, type IV collagen, fibronectin, and heparan sulfate
proteoglycan (HSPG) in P9 cells using dot blot analysis of total
cellular RNA. In addition, we characterized the effect of
carbo-prostacyclin on the expression of extracellular matrix
proteins using immunoprecipitation of newly synthesized pro-
teins. In general, the TXA2 analog U466l9 stimulated matrix
gene expression and protein production with the exception of
HSPG; in contrast to the other matrix genes, HSPG was
reduced by TXA2. The effects of carbo-prostacyclin were
generally the opposite of those obtained with TXA2. Carbo-
prostacyclin decreased the levels of matrix proteins with the
exception of RSPG and laminin B2, both of which were
increased. These studies indicated that the two arachidonic acid
metabolites TXA2 and PG!2 directly affect matrix gene expres-
sion independent of hemodynamic and platelet effects. Further-
more, the effects on expression are gene-specific and suggest
differential regulation in pathogenesis. This was particularly
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true for HSPG whose response to TXA2 and PGI2 was opposite
to that of the other matrix genes generally associated with the
basement membrane.
Methods
Cell culture
The F9 cell line [301 is derived from a murine teratocarcinoma
and is widely used as a model system for developmental and
inducible matrix gene expression. These cells do not express
matrix proteins until they are differentiated to an endodermal
phenotype (designated "F9") by dibutyryl cAMP and retinoic
acid. Differentiation results in a high level of expression of matrix
proteins including type IV collagen, laminin, heparan sulfate
proteoglycan (HSPG) and fibronectin [29, 3 1—341. F9 cells were
treated for four hours with varying doses of stable analogs of
TXA2 (U46619) and prostacyclin (carbo-prostacyclin). U46619
[(5Z,9a,l 1 a, l3E, l5(S)-15-hydroxy-9,(1 l)-methanoepoxyprosta-5,
l3-dienoic acid] and carbo-prostacyclin [(5Z,l la,13E,l5(S)-6,9a-
methano-l 1, 15-dihydroxy-prosta-5, 13-dien-1-oic acid] were ob-
tained from Cayman Chemical Company (Ann Arbor, Michigan,
USA). Both analogs were suspended in 95% ethanol.
Proliferation assays using [3Hj-thymidine incorporation were
performed as previously described [29] on subconfluent cells
following 18 of hours stimulation with 10 to 500 n carbo-
prostacyclin. This assay was performed in quadruplicate two
times and the data are presented as the mean standard
deviation.
Immunoprecipitations
F9 cells were grown to near confluence in 35 mm culture
dishes and incubated with varying concentrations of either
U46619 or carbo-prostacyclin. Newly synthesized extracellular
matrix proteins were detected by in vivo radiolabeling and
immunoprecipitation as described previously [29]. Immunopre-
cipitated proteins were resolved by electrophoresis under de-
naturing conditions using 5% polyacrylamide gels, followed by
autoradiography of the dried gels. Rabbit anti-mouse laminin,
heparan sulfate proteoglycan and type IV collagen antibodies
(polyclonal) were a gift from Dr. Hynda Kleinman (National
Institutes of Health, Bethesda, Maryland, USA).
RNA preparation and analysis
Total cellular RNA was prepared from F9 cells as described
by Chomczymski and Sacchi [35]. The RNA (5 g) was heated
for 10 minutes at 65°C, spotted on nylon membranes using a dot
blot manifold (Schleicher & Schuell, Keene, New Hampshire,
USA) in a buffer of 50% formamide, 6x SSC and 10 g/ml yeast
tRNA. The nylon membranes were cross linked by UV irradi-
ation, and were pre-incubated in a buffer composed of 50%
formamide, 0.1% SDS, 5 x SSPE, 100 g/ml sheared salmon
sperm DNA and 2 x Denhardt's solution for two hours at 37°C.
[32P}-labeled cDNA probes (l0 cpm/filter) were hybridized for
18 hours at 37°C in the above buffer containing 10% dextran
sulfate. After hybridization, the filters were washed twice in 6x
SSPE, 0.1% SDS for 15 minutes at room temperature, twice in
lx SSPE, 0.1% SDS for 15 minutes at room temperature, and
twice in 0.lx SSPE, 0.1% SDS for 15 minutes at 37°C. All
probes were derived from mouse cDNA clones unless other-
wise stated and were prepared as follows: The laminin A probe
was a 1.0 kb EcoRI fragment from clone AA-E3 [36]. The
laminin B! probe was a 1.0 kb HindIII/BglII fragment from
clone p24 [371. The laminin B2 probe was a 1.5 kb EcoRII
Hindill fragment from clone p7 [38]. The collagen iVal probe
was a 830 bp PstIIAvaI fragment from clone pFAC [391. The
heparan sulfate proteoglycan core protein probe was a 1.9 kb
EcoR! fragment from clone pBG 5 [40]. The fibronectin probe
was a 2.0kb EcoRI fragment from a human cDNA clone [41]. A
0.78 kb PstIIXbaI fragment from the human glyceraldehyde-3-
phosphate dehydrogenase gene ("GAPDH", ATCC# 57090)
was used to correct for any variation in the amount of RNA
spotted. These probes were shown by Northern analyses to be
specific for the intended RNA without cross reactivity as
previously described [29]. All fragments were radiolabeled
using a random prime kit (Pharmacia, Piscataway, New Jersey,
USA) as directed by the manufacturer. RNA was isolated and
blotted from three separate experiments and all RNA prepara-
tions were hybridized individually with each of the DNA
probes. The dot blots were quantitated by phosphorimage
analysis (Molecular Dynamics, Sunnyvale, California, USA).
The percent change from the unstimulated state was calculated,
and the statistical significance determined by analysis of vari-
ance.
Results
We have previously shown that incubation of F9 cells with
U46619, a stable analog of TXA2, increases the production of
the matrix proteins, laminin, type IV collagen and fibronectin
[29]. in the present study, we evaluated the effects of PG!2 on
matrix protein production and compared the effects of PG!2 to
TXA2 on matrix gene expression in F9 cells.
Treatment of F9 cells for four hours with 100 flM carbo-
prostacyclin significantly reduced the synthesis of type IV
collagen and laminin (Fig. 1). Previous studies with the TXA2
analog, U46619, revealed a stimulation in protein production of
type IV collagen, fibronectin and laminin A, B 1, and B2 in F9
and renal mesangial cells [29]. In contrast, to these other
extracellular matrix proteins, the production of HSPG protein
decreased with treatment of U466l9 and increased with treat-
ment of carbo-prostacyclin in a dose-dependent fashion (Fig. 2).
To determine whether these changes might be associated with
mitogenesis, as has been observed with PGE2 and human renal
mesangial cells in culture [42], we measured the effect of
carbo-prostacyclin on F9 cell proliferation after 18 hours.
Carbo-prostacyclin did not stimulate proliferation of F9 cells
as measured by [3H]-thymidine incorporation at 10, 100 or 500
n doses, the same dose range in which changes in extracellular
matrix synthesis were observed (Fig. 3).
To explore the differences in gene expression in response to
PGI2 and TXA2, RNA dot blots of total cellular RNA from
treated F9 cells were probed for fibronectin, type IV collagen,
HSPG and laminin chains A, Bl, and B2 (Figs. 4—6). A single
representative dose-response (25 to 500 nM) curve for U466l9
treatment is presented in Figure 4. The dot blots shown are
autoradiographic images, but the graphed data have been
generated from phosphorimage analysis of the individual filters
where counts per minute were measured directly. The initial
differences in hybridization intensity between the various
probes prior to incubation with eicosanoid (0 nM) reflected the
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Fig. 1. Effect of carbo-prostacyclin on Iaminin and type JV collagen production. Immunoprecipitation of newly synthesized proteins from F9
cells using polyclonal anti-laminin and anti-type IV collagen antibodies. Treatments were for 4 hours with 10 nM and 100 nM carbo-prostacyclin.
Molecular weight markers are given at the right. Abbreviations are: A, laminin A chain; BI, laminin B! chain; B2, laminin B2 chain; COLIV, type
IV collagen; kDa, kilodaltons.
relative abundance of each message type. The maximum re-
sponse of matrix protein mRNA to U46619 occurred in the
concentration range of SO to 100 nivi.
Similarly, F9 cells were incubated with various concentra-
tions of carbo-prostacyclin and matrix gene expression mea-
sured by dot-blot analysis (Fig. 5). Incubation with carbo-
prostacyclin decreased the steady-state mRNA levels for the
genes encoding type IV collagen, laminin A and B 1, and
fibronectin. In contrast, HSPG mRNA was increased by incu-
bation of cells with carbo-prostacyclin. In general, the effects of
carbo-prostacyclin (with the exception of laminin B2) were
opposite to those observed with U46619.
The results of three individual experiments performed with
100 nM U466l9 or carbo-prostacyclin were factored for control
expression of GAPDH and expressed as a percent change over
baseline steady state mRNA level (Fig. 6). Each bar represents
an average of the three experiments and an asterisk indicates a
statistically significant change (P < 0.05). Incubation of F9
cells with U466l9 increased the expression of genes encoding
most of the matrix proteins with the exception of HSPG.
Incubation with carbo-prostacyclin, however, decreased the
expression of these same genes with the exception of laminin
B2. In marked contrast to the other matrix genes, U466l9
decreased HSPG and carbo-prostacyclin increased HSPG ex-
pression.
Discussion
In the present study we have shown that TXA2 stimulates
steady state mRNA for the genes encoding type IV collagen,
taminin and fibronectin, but inhibits HSPG steady-state mRNA
level. Prostacyclin, in contrast, appears to suppress expression
of type IV collagen, fibronectin, and the laminin A and B I
chains. The HSPG and laminin B2 chain mRNA levels were
stimulated by incubation with prostacyclin. The effects of
thromboxane were substantially greater on a molar basis at
stimulating collagen IV and reducing HSPG than the counter-
balancing effects of prostacyclin. The effects of these ei-
cosanoids on matrix mRNA levels might be perceived as
relatively small (2- to 3-fold maximally during the 4 hr incuba-
tion). Over the course of a 15 year chronic illness such as
diabetes, however, small transcriptional changes in the genes
encoding extracellular proteins as well as post-transcriptional
modifications in mRNA or protein could easily result in large
structural changes in renal glomerular and tubular architecture.
In experimental models of chronic glomerular disease includ-
ing renal ablation, diabetic nephropathy, lupus nephritis, im-
mune complex disease, and PAN induced membranous ne-
phropathy [reviewed in 4], the deleterious effects of TXA2 have
been attributed either to its vasoconstrictor properties or to its
ability to induce platelet aggregation. Conversely, the benefits
of prostacyclin have been suggested to be due to its ability to
antagonize thromboxane or angiotensin-induced vasoconstric-
tion [43, 44] or to prevent thromboxane-induced platelet aggre-
gation. Our results suggest that TXA2 and PG!2 may also
directly affect matrix deposition in the glomerulus by influenc-
ing the expression of genes encoding extracellular matrix pro-
teins.
The direct effects of eicosanoids on matrix gene expression
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Fig. 2. Effect of U46619 and carbo-prostacyclin on heparan sulfate proteoglycan protein production. Immunoprecipitation of newly synthesized
proteins from F9 cells using a polyclonal anti-HSPG antibody (arrowhead). Treatments were for 4 hours with 1, 10 and 100 flM U46619 or
carbo-prostacyclin. Molecular weight markers are given at the right. Abbreviation is kDa, kilodaltons.
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Fig. 3. Effect of carbo-prostacyclin on F9 cell proliferation. F9 cells
were treated for 18 hours with 10, 100, or 500 ni carbo-prostacyclin
followed by a 4 hour pulse with [3H1.thymidine. Effects on prolifera-
tion, using changes in DNA synthetic rates, were determined by 3H
incorporation, This assay was performed in quadruplicate two times
and the data presented are the mean standard deviation.
appear to be particularly relevant to diabetes mellitus. As a
result of diabetes, alterations in the components of the base-
ment membrane contribute to systemic changes in capillary
permeability that are most apparent in glomerular and retinal
basement membrane. The majority of evidence suggests that
diabetes is associated with a loss of heparan sulfate proteogly-
can and an increase in the other components of basement
membrane at the protein level [45—49]. While this may occur as
a result of changes in both synthesis and degradation of matrix
proteins, recent evidence suggests that these changes in protein
are reflected by similar changes in mRNA [50—521. For exam-
ple, the steady-state mRNA level of HSPG is decreased while
steady-state mRNA levels of collagen IV and I as well as
laminin B 1 are increased in glomeruli isolated from streptozo-
tocin-induced diabetic rats. In the KKay strain of spontane-
ously diabetic mice, the ratio of steady-state mRNA for HSPG/
collagen IV is decreased [51]. Thus, diabetes mellitus produces
systemic changes in basement membrane characterized by a
decrease in HSPG and an increase in laminin and collagen that
appears to be both at the protein and mRNA level.
Diabetes mellitus also produces a marked change in renal
eicosanoid metabolism. Diabetic nephropathy is associated
with an increase in renal thromboxane production and throm-
boxane has been shown to affect renal hemodynamics in
diabetic rats [reviewed in 4]. Prostacyclin is also increased early
in the course of diabetes and participates in diabetic hyperfil-
tration. Later in the disease, however, prostacyclin may not be
increased and may fall to previous levels [53], Furthermore,
incubation of KKay mice with a thromboxane synthetase
inhibitor decreases collagen IV steady-state mRNA levels [51].
The beneficial effects of thromboxane synthetase inhibition
were attributed to a reduction in thromboxane production since
urinary excretion of thromboxane in these mice was reduced. If
significant substrate shunting occurred [54, 551, however, pros-
tacyclin may have been increased by this intervention as well.
Thus, while it is clear that PGI2 and TXA2 are important
modulators of renal hemodynamic function in diabetic nephrop-
athy, the findings reported here suggest a potentially important
direct role for these autacoids in the development of chronic
glomerular sclerosis.
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Fig. 4. Dose response of U46619 treatment
on steady-state mRNA levels. F9 cells were
treated with varying amounts of U46619, total
cellular RNA was isolated, spotted on nylon
membranes and hybridized with probes for
the matrix proteins. The right panel is an
autoradiogram of the hybridized membrane,
Phosphorimage analysis of the hybridized
membrane was used to determine the amount
of radioactivity of each dot and is shown in
the graph. Abbreviations are: A, laminin A
chain; B!, laminin B! chain; B2, laminin B2
chain; COLIV, type IV collagen; FN,
fibronectin; HSPG, heparan sulfate
proteoglycan.
Fig. 5. Dose response of carbo-prostacyclin
treatment on steady-state mRNA levels. F9
cells were treated with varying amounts of
carbo-prostacyclin, total cellular RNA was
isolated, spotted on nylon membranes and
hybridized with probes for the matrix
proteins. The right panel is an autoradiogram
of the hybridized membrane. Phosphorimage
analysis of the hybridized membrane was used
to determine the amount of radioactivity of
each dot and is shown in the graph.
Abbreviations are: A, laminin A chain; Bl,
laminin Bi chain; B2, laminin B2 chain;
COLIV, type IV collagen; FN, fibronectin;
HSPG, heparan sulfate proteoglycan.
Fig. 6. Comparison of the effects of U46619
and carbo-prostacyclin treatment on the
expression of matrix proteins. Each bar
represents the mean standard deviation of 3
experiments; the asterisk above the bar
indicates a statistically significant change of P
<0.05. The data used in the graph were
adjusted to the level of a control probe
(GAPDH) to account for any errors in mRNA
quantitation or spotting. (The data presented
in the graphs are relative to the control
whereas the autoradiograms from Figures 4
and 5 represent primary counts). The percent
change was calculated from the unstimulated
state to the 100 nM dose. Abbreviations are:
A, laminin A chain; BI, laminin Bi chain; B2,
laminin B2 chain; COLIV, type IV collagen;
FN, fibronectin; HSPG, heparan sulfate
proteoglycan.
The present findings suggest that regulation of extracellular
matrix genes by eicosanoids is complex. Thromboxane and
prostacyclin not only affect gene expression in an opposing
fashion, the response of HSPG mRNA to these eicosanoids is
different from the other extracellular matrix genes. Thus, the
net effect of TXA2 and PGI2 is target gene-dependent. The
present results support a direct role for eicosanoids in the
modulation of extracellular matrix genes in sclerosing diseases
in general (for example, skin, kidney, liver, lung, and heart).
They also provide an additional rationale for therapy directed at
specific inhibition of thromboxane.
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